US20170107299A1

US20170107299A1 - Anti-vasa antibodies, and methods of production and use thereof

Info

Publication number: US20170107299A1
Application number: US15/395,114
Authority: US
Inventors: David T. Weaver; Bo Zhang
Original assignee: Ovascience Inc
Current assignee: Millendo Therapeutics Inc
Priority date: 2014-09-16
Filing date: 2016-12-30
Publication date: 2017-04-20
Also published as: WO2016044436A3; AU2015317813B2; EP3194448A2; US9567404B2; CR20170067A; CA2959179A1; EP3194448A4; KR20170056521A; CL2017000402A1; DOP2017000050A; GT201700036A; US9403913B2; WO2016044436A2; SG11201701016WA; MX2017002390A; TW201619194A; MX358243B; JP2018148915A; BR112017003263A2; US20160075797A1

Abstract

Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

Description

This application is a continuation of U.S. application Ser. No. 15/203,040, filed Jul. 6, 2016, which is a continuation of U.S. application Ser. No. 14/856,380, filed Sep. 16, 2015 (now U.S. Pat. No. 9,403,913), which claims the benefit of priority of U.S. Provisional Application No. 62/089,054, filed Dec. 8, 2014, and U.S. Provisional Application No. 62/051,130, filed Sep. 16, 2014, the entire contents of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present disclosure relates generally to antibodies, their production and use. Specifically, the present disclosure pertains to antibodies which specifically bind to the human VASA protein, methods of producing such antibodies, and diagnostic, therapeutic and clinical methods of using such antibodies.

BACKGROUND

The VASA protein was identified in Drosophila as a component of the germplasm that encodes a DEAD-family ATP-dependent RNA helicase (Liang et al. (1994), Development, 120:1201-11; Lasko et al. (1988), Nature 335:611-17). The molecular function of VASA is directed to binding target mRNAs involved in germ cell establishment, oogenesis, and translation onset (Gavis et al. (1996), Development 110:521-28). VASA is required for pole cell formation and is exclusively restricted to the germ cell lineage throughout development.
Vasa homolog genes have been isolated in various animal species, and VASA can be used as a molecular marker for the germ cell lineage in most animal species (Noce et al. (2001), Cell Structure and Function 26:131-36). Castrillon et al. (2000), Proc. Natl. Acad. Sci. (USA) 97(17):958590-9590, for example, demonstrated that the human Vasa gene is expressed in ovary and testis but is undetectable in somatic tissues.
The existence of mammalian female germline stem cells, also known as oogonial stem cells or ovarian stem cells (OSCs) or egg precursor cells, in the somatic tissue of mammalian ovaries was first described in Johnson et al. (2004), Nature 428:145-50, and has now been confirmed by other research groups (e.g., Zou et al. (2009), Nature Cell Biology, published online DOI: 10.1038/ncb1869; Telfer & Albertini (2012), Nature Medicine 18(3):353-4). The potential use of OSCs to produce oocytes for use in artificial reproduction technologies (ART), including in vitro fertilization (IVF), or as sources of highly functional mitochondria for mitochondrial transfer to oocytes, as well as the use of OSCs to treat various symptoms of menopause, have been described in the scientific and patent literature (e.g., Tilly & Telfer (2009), Mol. Hum. Repro. 15(7):393-8; Zou et al. (2009), supra; Telfer & Albertini (2012), supra; White et al. (2012), Nature Medicine 18(3):413-21; WO 2005/121321; U.S. Pat. No. 7,955,846; U.S. Pat. No. 8,652,840; WO2012/142500; U.S. Pat. No. 8,642,329 and U.S. Pat. No. 8,647,869).
When OSCs were first characterized by Johnson et al. (2004), supra, it was demonstrated that the cells expressed the VASA protein, and antibodies against the VASA protein have been used to isolate OSCs from ovarian tissue homogenates (e.g., Zou et al. (2009), supra; White et al. (2012), supra). Moreover, White et al. (2012), supra, demonstrated that antibodies to an N-terminal domain of VASA could not be used to isolate viable VASA-expressing OSCs whereas antibodies to a C-terminal domain could effectively isolate the cells, suggesting that the C-terminal domain, but not the N-terminal domain, was extracellular and thus accessible to the antibodies.
The production of anti-VASA polyclonal antibodies was first described in Castrillon et al. (2000), supra, and WO01/36445. Polyclonal antibodies directed to the C-terminal portion of human VASA protein are commercially available from Abcam plc (Cambridge, UK; Product Code AB13840), and R&D Systems, Inc. (Minneapolis, Minn.; Catalog No. AF2030), and a monoclonal antibody directed against the N-terminal portion of human VASA is also commercially available from R&D Systems, Inc. (Minneapolis, Minn.; Catalog No. AF2030),
There remains, however, a need for high affinity antibodies directed to the C-terminal extracellular domain of VASA for identifying (e.g., by immunohistochemistry or labeled antibodies) and isolating (e.g., by magnetic or fluorescence activated cell sorting) cells, including but not limited to OSCs, expressing VASA.

SUMMARY

Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.
These and other aspects and embodiments of the disclosure are illustrated and described below. Other systems, processes, and features will become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional systems, processes, and features be included within this description, be within the scope of the present invention, and be protected by the accompanying claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides the amino acid sequence of the human VASA protein isoform 1 from GenBank Accession from NP_077726 (SEQ ID NO: 1).

FIG. 2 provides the amino acid sequence of the mouse VASA homolog protein isoform 1 from GenBank Accession from NP_001139357 (SEQ ID NO: 2).

FIG. 3 provides an amino acid alignment between the C-terminal portion of the human VASA protein (residues 690-724 of SEQ ID NO: 1) and the mouse VASA homolog (residues 691-728 of SEQ ID NO: 2).

FIG. 4A shows the region of the C-terminal domains of the VASA/DDX4 polypeptide that is reactive with an antibody of the invention and the control antibody (AB13840, Abcam plc, Cambridge, UK) and FIG. 4B shows binding of the control antibody to the VASA protein and the V1 and V2 polypeptides.

FIG. 5A shows dose response binding curves of the affinity for VASA of 1E9 and 1A12; and FIG. 5B shows the results of ELISA assays with the VASA, V1 and V2 peptides that suggest that 1E9 binds the same epitope as the commercially available rabbit polyclonal antibody (AB13840, Abcam plc, Cambridge, UK). NC=negative control; VASA=SEQ ID NO: 1 residues 700-724; VASA-1=V1 or SEQ ID NO: 1 residues 712-721; VASA-2=V2 or SEQ ID NO: 1 residues 700-709.

FIG. 6A shows dose response binding curves of the affinity for VASA of the IgG and scFv-Fc forms of 1E9; and FIG. 6B shows the results of ELISA assays of the binding of the IgG and scFv-Fc forms of 1E9 with the VASA, V1 and V2 peptides. NC=negative control; VASA=SEQ ID NO: 1 residues 700-724; VASA-1=V1 or SEQ ID NO: 1 residues 712-721; VASA-2=V2 or SEQ ID NO: 1 residues 700-709.

FIG. 7A shows the results of binding experiments with three anti-VASA hybridoma antibodies (2M1/1K3, 2M1/1K23 and 2M1/1L5) and two negative controls (2M1/1F5 and 2M1/1H5) which are not VASA-specific; FIG. 7B shows dose response curves of four VASA-specific hybridoma antibodies (2M1/1K3, 2M1/1K23 and 2M1/1L5) compared to 1E9-lambda; and FIG. 7C shows dose response curves of the VASA-specific hybridoma antibody 2M1/2K4 compared to 1E9-lambda.

FIG. 8 shows the result of subtyping analysis for anti-VASA antibodies from eight hybridomas (2M1/1L20, 2M1/1J20, 1M1/1C9, 2M1/1N3, 2M1/1K23, 1M1/1L5 and 2M1/2K4).

FIGS. 9A-9B show alignments of some of the VL sequences of the anti-VASA invention. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.

FIGS. 10A-10B show alignments of some of the VH sequences of the anti-VASA invention. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.

FIG. 11 shows alignments of the unique CDR sequences of the VL regions of FIG. 9.

FIG. 12 shows alignments of the unique CDR sequences of the VH regions of FIG. 10.

DETAILED DESCRIPTION

The present disclosure relates to isolated antibodies (Abs), particularly Abs that bind specifically to VASA with high affinity. In certain embodiments, the anti-VASA Abs are derived from particular heavy and light chain sequences and/or comprise particular structural features, such as CDR regions comprising particular amino acid sequences. This disclosure provides isolated anti-VASA Abs, methods of making such anti-VASA Abs, immunoconjugates and bispecific molecules comprising such anti-VASA Abs, and methods of expressing such anti-VASA Abs. This disclosure also relates to methods of using the anti-VASA Abs to isolate and/or purify cells expressing VASA, including mammalian female germline stem cells or oogonial stem cells (OSCs) or egg precursor cells and their progenitor cells.
In order that the present disclosure may be more readily understood, certain terms are defined. Additional definitions are set forth throughout the detailed description.

DEFINITIONS

The term “antibody” or abbreviation “Ab,” as used herein, includes whole antibodies and any antigen binding fragment (i.e., “antigen-binding portion”) or single chains thereof, with or without native glycosylation. A complete “antibody” refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds or an antigen binding portion thereof. Each heavy chain includes a heavy chain variable region (V_H) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, C_H1, C_H2, and C_H3. Each light chain includes a light chain variable region (V_L) and a light chain constant region with one domain, C_L. The V_Hand V_Lregions can be further subdivided into complementarity determining regions (CDR) and framework regions (FR). The V_Hand V_Lregions each include three CDRs, designated CDR1, CDR2 and CDR3, that interact with an antigen (e.g., VASA).
The term “antigen-binding portion” of an antibody, as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., VASA). Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include a Fab fragment, F(ab′)₂fragment, Fab′ fragment, Fd fragment, Fv fragment, scFv fragment, dAb fragment, and an isolated CDR.
The term “monoclonal antibody” or “monoclonal antibody preparation,” as used herein, refers to a preparation of antibody molecules consisting essentially of antibodies having a single heavy chain amino acid sequence and a single light chain amino acid sequence (but which may have heterogeneous glycosylation).
The term “humanized antibody,” as used herein, includes antibodies having constant region and variable region framework regions (FRs) but not CDRs derived from human germline immunoglobulin sequences.
The term “recombinant antibody,” as used herein, includes all antibodies prepared, expressed, created, or isolated by recombinant means. In certain embodiments, recombinant antibodies are isolated from a host cell transformed to express the antibody (e.g., from a transfectoma). In other embodiments, recombinant antibodies are isolated from a recombinant, combinatorial antibody library, such as a phage display library. Recombinant antibodies may also be prepared, expressed, created, or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences.
The term “isotype,” as used herein, refers to the heavy chain class (e.g., IgA, IgD, IgE, IgG, and IgM for human antibodies) or light chain class (e.g., kappa or lambda in humans) encoded by the constant region genes. The term “subtype” refers to subclasses within the subtype (e.g., IgA₁, IgA₂, IgG₁, IgG₂, IgG₃, IgG₄in humans).
The phrase “an antibody specific for” a specified antigen is used interchangeably herein with the phrase “an antibody which specifically binds to” a specified antigen. As used herein, the term “K_a” refers to the association rate and the term “K_d” to the dissociation rate of a particular antibody-antigen complex. The term “K_D” refers to the dissociation constant, which is obtained from the ratio of K_dto K_aand expressed as a molar concentration (M). According to some embodiments, an antibody that “specifically binds to human VASA” is intended to refer to an antibody that binds to human VASA with a K_Dof 5×10⁻⁸M or less, more preferably 1×10⁻⁸M or less.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Anti-VASA Antibodies

The invention provides a variety of new antibodies with high affinity against the human VASA protein, particularly the C-terminal region. The antibodies may comprise the complete VH and VL regions disclosed herein, or may comprise only the CDR sequences disclosed herein. In addition, based upon CDR sequences disclosed herein, sequence motifs for CDR sequences are provided, and the antibodies may comprise CDR sequences defined by the motifs.
The CDR sequences of the invention (including both the CDRs disclosed in FIGS. 11 and 12 and the CDRs defined by the sequence motifs disclosed herein) can be combined with other immunoglobulin sequences according to methods well known in the art to produce immunoglobulin molecules with antigen-binding specificity determined by the CDRs of the invention.
In some embodiments, the CDRs of the invention are combined with framework region (FR) and constant domain (CH or CL) sequences from other antibodies. For example, although some of the CDRs disclosed herein are derived from murine hybridomas and have murine FR and constant domain sequences, they can be recombined with human or other mammalian FR and constant domain sequences to produce humanized or other recombinant antibodies. The production of such recombinant antibodies is well known to those of skill in the art and requires only routine experimentation.
The type of constant regions included in such recombinant antibodies can be chosen according to their intended use. For example, if the antibodies are intended for therapeutic use to target VASA-expressing cells for destruction, heavy chain constant domains (i.e., Fc regions) of IgG subtypes can be used. If the antibodies are intended only as reagents for labeling cells (e.g., for fluorescence-activated cell sorting (FACS)), a complete antibody, antigen binding fragment (Fab), single-chain variable fragment (Fsc), single domain antibody (sdAb) or even non-antibody immunoglobulin molecule (e.g., an MHC receptor extracellular domain) can be used with the CDRs of the invention.
The CDRs of the invention can be selected independently such that the CDR1, CDR2 and CDR3 sequences of a given variable light (VL) chain or variable heavy (VH) chain can be chosen from different original VL and VH chains, from different VL and VH CDR motifs, or from a combination of the disclosed CDRs and motifs. However, sequences for light chain CDRs should be selected from the disclosed VL CDRs or VL CDR motifs, and sequences for heavy chain CDRs should be selected from the disclosed VH CDRs or VH CDR motifs. Similarly, the sequences for CDR1 regions should be selected from the disclosed CDR1 or CDR1 motif sequences, the sequences for CDR2 regions should be selected from the disclosed CDR2 or CDR2 motif sequences, and the sequences for CDR3 regions should be selected from the disclosed CDR3 or CDR3 motif sequences, for VL or VH chains as appropriate.

Methods of Using Anti-VASA Antibodies to Detect or Isolate Cells

The anti-VASA antibodies of the invention can be used in standard methods of immunoaffinity purification, immunohistochemistry and immunotherapy, but with specific application to cells and tissue expressing the VASA protein.
For example, the anti-VASA antibodies of the invention can be used to isolate cells expressing VASA from a mixed population of cells including only a fraction of cells that express VASA. For example, female germline stem cells or oogonial stem cells or their precursors have been discovered to be present in ovarian tissue at very low proportions. Ovarian tissue (e.g., ovarian surface epithelial and/or cortex) can be excised, dissociated into individual cells, and subjected to techniques such as FACs using fluorescently-labeled anti-VASA antibodies or immunoaffinity purification using immobilized anti-VASA antibodies. The isolated VASA-expressing cells have various utilities in assisted reproductive technologies, as described above.
Alternatively, immunohistochemistry may be performed using the anti-VASA antibodies of the invention to identify cells or tissues expressing VASA and/or to quantify VASA expression in such cells.
In addition, the anti-VASA antibodies of the invention can be used therapeutically to target VASA-expressing cells for destruction either by antibody-dependent cell-mediated cytotoxicity (ADCC) or immunotoxins comprising anti-VASA antibodies of the invention conjugated to radio- or chemo-toxic moieties. Antibody-drug conjugates of the anti-VASA antibodies of the invention could also be used to deliver therapeutic drugs to VASA-expressing cells.

Nucleic Acid Molecules Encoding Anti-VASA Antibodies

The invention also provides nucleic acid molecules encoding the anti-VASA antibodies of the invention. Such nucleic acids can be designed using standard tables for the universal genetic code to choose codons which will encode the desired amino acid sequence, or specialized codon tables can be used that reflect codon biases characteristic of different organisms. Thus, for example, to optimize expression of the anti-VASA antibodies of the invention in CHO cells, a nucleic acid encoding the desired antibody can be designed using a codon table optimized for CHO cells.
The nucleic acids encoding the anti-VASA antibodies of the invention can be included in a wide variety of vectors known in the art, including cloning vectors (e.g., bacterial or mammalian cloning vectors), transformation vectors (e.g., homologous recombination, viral integration or autonomously replicating vectors) and expression vectors (e.g., high copy number, inducible or constitutive mammalian expression vectors).

Cells Expressing Anti-VASA Antibodies

Also provided are host cells expressing heterologous sequences encoding the anti-VASA antibodies of the invention. Such host cells can be useful for commercial production of the anti-VASA antibodies of the invention, and can be produced by transforming appropriate host cells with expression vectors described above.
In some embodiments the invention provides mammalian cells, including CHO cells, expressing the anti-VASA antibodies of the invention. However, those of skill in the art can express the antibodies in a variety of host cells, including bacterial, yeast, insect and mammalian systems. See, e.g., Verma et al. (1998), J. Immunol. Methods 216(1-2):165-81, incorporated by reference in its entirety herein.

Examples

Immunogenic Peptides

The following peptides were used as immunogens to generate antibodies against the C-terminal domain of human VASA and to screen for antibodies with high affinity binding to VASA:

	VASA-1 (V1) immunogen:
	(SEQ ID NO: 1 residues 712-721)
	SQAPNPVDDE

	VASA-2 (V2) immunogen:
	(SEQ ID NO: 1 residues 700-709)
	GKSTLNTAGF

As shown in FIG. 3, these immunogens comprise amino acid sequences from the C-terminal domain of VASA that are highly conserved between the human VASA protein and the mouse VASA homolog.

Hybridoma Generation

Hybridomas were formed in separate experiments with the VASA peptide immunogens V1 and V2 (above). Peptides were conjugated to carrier proteins by standard methods. Conjugated peptides were used to immunize mice, and to increase the immune response through boosting with the conjugated peptide. Following a period of increased antibody titer in the sera, animals were sacrificed and spleens removed. Splenic B cells were fused to mouse fusion partner cell lines (SP2-0) for isolation and cloning. Hybridomas were formed by outgrowth at limiting dilution, and clones were developed by cloning titration experiments. The presence of VASA-reactive antibodies was examined by ELISA assays. Hybridomas were derived by outgrowth and stabilization of cells plated at limiting dilution cell cloning.
The binding of the VASA-reactive antibodies in the region of the C-terminal domains of the VASA/DDX4 polypeptide was compared with the binding control antibodies (AB13840, Abcam plc, Cambridge, UK) to delineate the similarity of the binding epitopes. Exemplary results are shown in FIG. 4.

Analysis of Hybridomas

Hybridomas were injected intraperitoneally into mice and, after allowing for a period of growth, ascites fluid was collected and purified, all using standard procedures, and then analyzed by ELISA.
Binding of the ascites-derived antibodies to the VASA, VASA-1 and VASA-2 polypeptides was used to select antibodies for further analysis. For example, as shown in FIG. 7, the binding of four anti-VASA hybridoma antibodies (2M1/1K3, 2M1/1K23, 2M1/1L5 and 2M1/2K4) were compared to two negative controls (2M1/1F5 and 2M1/1H5) which are not VASA-specific and/or to the 1E9-lambda antibody (described below).

Recombinant Library Panning

As an alternative to hybridoma technology, the generation of antibodies against amino acid residues 700-724 of human VASA/DDX4 was conducted using phage display technology. The phage display library was formed from a pool of normal B cells from ˜40 blood donors. Phage were used to display the scFv chain of an antibody
The results of panning the human naive scFv library against the VASA/DDX4 700-724 peptide were as shown in Table 1 below:

TABLE 1

		Titer of output	Titer of rescued
Peptide	Round	phage (cfu/ml)	phage (cfu/ml)	ELISA results

VASA	1^st	10⁷	10¹³	/
	2^nd	10⁷	10¹³	/
	3^rd	10⁷	10¹²	No positive
				clones

	4^th	10⁷	10¹³	Two positive
				clones
	5^th	10⁷	10¹³	Several
				positive clones
	6^th	10⁷	/	/

ELISA results of single colonies identified after 3 and 4 rounds of selection are shown in Tables 2-4 below. Two clones were of note: “1A12” (plate 1, row A, column 12) and “1E9” (plate 1, row E, column 9).

TABLE 2

TABLE 3

plate 2-after 4 round of selection

	1	2	3	4	5	6	7	8	9	10	11	12

VASA peptide

A.	0.052	0.045	0.053	0.045	0.051	0.045	0.046	0.044	0.049	0.044	0.045	0.050
B.	0.049	0.051	0.051	0.045	0.042	0.054	0.046	0.045	0.055	0.045	0.048	0.053
C.	0.048	0.047	0.048	0.054	0.051	0.047	0.047	0.045	0.047	0.052	0.051	0.055
D.	0.062	0.050	0.048	0.047	0.059	0.056	0.059	0.063	0.048	0.057	0.052	0.061
E.	0.047	0.042	0.042	0.045	0.051	0.041	0.047	0.042	0.044	0.052	0.050	0.054
F.	0.047	0.049	0.040	0.042	0.046	0.043	0.046	0.042	0.052	0.045	0.051	0.054
G.	0.047	0.052	0.045	0.041	0.039	0.051	0.048	0.049	0.052	0.043	0.054	0.050
H.	0.055	0.048	0.054	0.042	0.043	0.048	0.048	0.049	0.051	0.051	0.048	0.054

non-relevant peptide

A.	0.047	0.053	0.050	0.042	0.053	0.053	0.041	0.043	0.042	0.053	0.053	0.054
B.	0.052	0.053	0.054	0.054	0.053	0.043	0.043	0.045	0.053	0.045	0.055	0.054
C.	0.052	0.047	0.054	0.053	0.055	0.045	0.045	0.043	0.053	0.055	0.057	0.053
D.	0.047	0.049	0.054	0.056	0.047	0.049	0.054	0.051	0.056	0.062	0.065	0.062
E.	0.052	0.045	0.042	0.045	0.041	0.051	0.040	0.047	0.041	0.056	0.053	0.054
F.	0.052	0.053	0.041	0.045	0.052	0.053	0.054	0.052	0.533	0.049	0.045	0.053
G.	0.051	0.053	0.049	0.050	0.051	0.043	0.049	0.052	0.053	0.053	0.054	0.051
H.	0.055	0.052	0.054	0.053	0.045	0.051	0.051	0.051	0.052	0.062	0.054	0.053

TABLE 4

plate 3-after 4 rounds of selection

	1	2	3	4	5	6	7	8	9	10	11	12

VASA peptide

A.	0.074	0.052	0.058	0.076	0.052	0.063	0.052	0.055	0.040	0.052	0.054	0.072
B.	0.047	0.041	0.052	0.064	0.072	0.051	0.059	0.048	0.053	0.048	0.054	0.053
C.	0.051	0.042	0.042	0.044	0.053	0.056	0.052	0.048	0.044	0.048	0.060	0.056
D.	0.057	0.049	0.045	0.051	0.053	0.046	0.067	0.047	0.046	0.046	0.059	0.058
E.	0.054	0.046	0.042	0.126	0.041	0.047	0.051	0.040	0.042	0.043	0.048	0.073
F.	0.077	0.045	0.040	0.047	0.042	0.040	0.042	0.039	0.041	0.053	0.051	0.051
G.	0.178	0.056	0.044	0.041	0.051	0.050	0.055	0.042	0.042	0.051	0.044	0.052
H.	0.054	0.042	0.045	0.041	0.049	0.039	0.045	0.089	0.050	0.051	0.061	0.055

non-relevant peptide

A.	0.050	0.056	0.055	0.049	0.053	0.055	0.051	0.059	0.051	0.044	0.047	0.054
B.	0.058	0.075	0.061	0.064	0.073	0.061	0.053	0.054	0.059	0.056	0.059	0.063
C.	0.076	0.056	0.053	0.054	0.056	0.053	0.053	0.053	0.057	0.063	0.049	0.061
D.	0.069	0.052	0.052	0.058	0.056	0.048	0.059	0.059	0.056	0.052	0.051	0.056
E.	0.047	0.056	0.050	0.118	0.063	0.067	0.052	0.053	0.054	0.053	0.056	0.054
F.	0.053	0.054	0.054	0.052	0.054	0.054	0.053	0.053	0.043	0.056	0.046	0.056
G.	0.063	0.056	0.054	0.045	0.045	0.049	0.050	0.053	0.053	0.052	0.055	0.053
H.	0.058	0.055	0.054	0.047	0.053	0.048	0.050	0.051	0.054	0.053	0.053	0.058

ELISA results of single colonies identified after 5 rounds of selection are shown in Tables 5-7 below. Clones of note included 1A11, 1B4, 1B7, 1D4, 1D5, 1E2, 1E3, 1F7, 1G3, 1G12, 2B8, 2C7, 2E11, 2F1, 2G8, 2G10, 2H9, 3B2, 3B5, 3B7, 3D11, 3E5, 3E12, 3F6 and 3H11.

TABLE 5

TABLE 6

TABLE 7

Clones shown in bold were PCR amplified.
Conversion to scFv-Fc Fusion and Expression in Mammalian Cells
After 5 rounds of panning, DNA digestion patterns showed that many clones from the 5^thround of panning were the same, indicating that additional rounds of selection and ELISA analysis were not needed.
Two unique clones (1A12, 1E9) were selected for conversion to scFv-Fc fusions for expression in mammalian cells and for ELISA and FACS analysis. FIG. 5A shows dose response binding curves that indicated that 1E9 had an EC50 of 0.02779 nM and 1A12 had an EC50 of 0.2156 nM. In addition, FIG. 5B shows the results of ELISA assays with the V1 and V2 VASA peptides which suggest that 1E9 binds the same epitope as the commercially available rabbit polyclonal antibody (AB13840, Abcam plc, Cambridge, UK).
Two different forms of the 1E9 antibody were compared: IgG and scFv-Fc. As shown in FIG. 6A, 1E9 IgG had an EC50 of 0.08919 nM and the 1E9 scFv-Fc had an EC50 of 0.3072 nM. In addition, as shown in FIG. 6B, both forms were specific towards the VASA-1 epitope.

Synthetic Antibody Gene Production

The following steps were employed to produce synthetic antibody genes:
(1) Subtype Determination of Hybridoma Antibodies.
The IgG subtypes of the hybridoma antibodies were determined using commercially available kits according to manufacturer's protocols (e.g., Mouse Monoclonal Antibody Isotyping Kit, Catalog No, AbDSerotech, Kidlington, UK). FIG. 8 shows the result of subtyping analysis for anti-VASA antibodies from eight hybridomas (2M1/1L20, 2M1/1J20, 1M1/1C9, 2M1/1N3, 2M1/1K23, 1M1/1L5 and 2M1/2K4). All of the antibodies were IgG1, IgG2a or IgG2b.
(2) Degenerate Primer Synthesis.
Based on the subtype information for the eight hybridoma antibodies tested, degenerate primers for mouse IgG VH and VL were designed using sequence information from a mouse IgG database (i.e., the International Immunogenetics Information System® or MGT database; see Lefranc et al. (2003), Leukemia 17:260-266, and Alamyar et al. (2012), Methods Mol. Biol. 2012; 882:569-604). Ten degenerate forward primers were designed and synthesized for the VH chain and ten for the VL chain (9 for kappa and one for lambda chains). In addition, two degenerate reverse primers for the VH chain (one for the IgG1 and IgG2b subtypes, and one for the IgG2a subtype) and five for the VL chain (four for kappa and one for lambda chains) were designed and synthesized.
(3) RNA Extraction, Amplification, Cloning and Sequencing.
RNA was extracted from hybridoma cells by standard techniques, first strand cDNA synthesis was performed by standard techniques using gene-specific and oligo(dT) primers, and the cDNA was amplified using gene-specific primers. The amplified DNA was then ligated into a commercially available bacterial cloning vector (pMD18-T, Sino Biological, Inc., Beijing, China). Standard methodologies were conducted to transform the ligation products into E. coli DH5α, and to sequence positive clones.

Antibody Sequence Analyses

Clones producing potentially useful anti-Vasa antibodies were DNA sequenced and the corresponding amino acid sequences were deduced. Sequences are disclosed for eight antibodies derived from the hybridomas described above (i.e., 1N23, 1K23, 2K4, 1C9, 1J20, 1L20, 1K3, 1L5), four additional antibodies derived from hybridomas produced under contract (i.e., CTA4/5, CTB4/11, CTC2/6, CTD2/6) and two antibodies derived from phage display (i.e., 1A12 and 1E9).
Variable Light Chain Sequences
VL of 1N23. Positive VL clones from the 1N23 hybridoma were sequenced and six were found to encode functional VL chains. These six clones were designated 1N23VL5-5, 1N23VL5-8_0816, 1N23VL1-8, 1N23VL1-2_0820, 1N23VL1-4_0820 and 1N23VL1-2.
VL of 1K23. Positive VL clones from the 1K23 hybridoma were sequenced and four were found to encode functional VL chains. These four clones were designated 1K23VL2-5, 1K23VL2-6, 1K23VL2-8_0822 and 1K23VL2-3_0829.
VL of 2K4. Positive VL clones from the 2K4 hybridoma were sequenced and eight were found to encode functional VL chains. These eight clones were designated 2K4VL1-3_0820, 2K4VL1-4, 2K4VL1-1, 2K4VL1-6_0820, 2K4VL2-5_0816, 2K4VL2-4, 2K4VL2-6_0816 and 2K4VL2-5.
VL of 1C9. Positive VL clones from the 1C9 hybridoma were sequenced and three were found to encode functional VL chains. These three clones were designated 1C9VL2-4, 1C9VL2-6 and 1C9VL2-3_0816.
VL of 1J20. Positive VL clones from the 1J20 hybridoma were sequenced and three were found to encode functional VL chains. These three clones were designated 1J20VL5-2_0907, 1J20VL5-6_0907 and 1J20VL4-3_0907.
VL of 1L20. Positive VL clones from the 1L20 hybridoma were sequenced and one was found to encode a functional VL chain. That clone was designated 1L20VL5-0912_091.
VL of 1K3. Positive VL clones from the 1K3 hybridoma were sequenced and four were found to encode functional VL chains. These four clones were designated 1K3VL2-5, 1K3VL2-5, 1K3VL2-3 and 1K3VL2-4.
VL of 1L5. Positive VL clones from the 1L5 hybridoma were sequenced and two were found to encode functional VL chains. These two clones were designated 1L5VL2-4 and 1L5VL3-1.
Additional VLs. VL sequences were obtained for four additional hybridoma antibodies designated CTA4_VL, CTB4_VL, CTC6_VL, CTD6_VL.
VL Sequence Alignments. Alignments of all of the VL sequences described above are shown in FIG. 9. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.
Unique VL CDR Sequences. Alignments of the unique CDR sequences of the VLs of FIG. 9 are shown in FIG. 11. Of the 34 VL sequences, there are only 5 unique CDR1 sequences, 6 unique CDR2 sequences and 8 unique CDR3 sequences, as shown in FIG. 11.
VL CDR Consensus Sequences. Based on the sequences disclosed in FIG. 11, as well as structure/function characteristics of the naturally occurring amino acids, consensus sequences for the VL CDRs can be determined.
One consensus sequence is VL CDR1 Motif 1:
(SEQ ID NO: 132)

X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁

where X₁is Q, N, K, R, S or T; X₂is S, T, C, N or Q; X₃is I, L, V, M or A; X₄is V, L, I, M, A or absent; X₅is H, K, R or absent; X₆is S, T, C or absent; X₇is N, Q or absent; X₈is G, A or absent; X₉is N or Q; X₁₀is T, S, C, N or Q; and X₁₁is Y, F or W. In some embodiments, X₁is limited to Q, K or S; and/or X₂is limited to S or N; and/or X₃is limited to I or L; and/or X₄is limited to V, L or absent; and/or X₅is limited to H or absent; and/or X₆is limited to S or absent; and/or X₇is limited to N or absent; and/or X₈is limited to G or absent; and/or X₉is limited to N; and/or X₁₀is limited to T, S or N; and/or X₁₁is limited to Y or F. In some embodiments, the subsequence X₁X₂X₃is limited to Q N I; in some embodiments, the subsequence X₁X₂X₃is limited to Q S L; and in some embodiments, the subsequence X₁X₂X₃is limited to K S L. In addition, in some embodiments, when X₁X₂X₃is Q S L or Q N I, then X₄is V; whereas in other embodiments, when X₁X₂X₃is K S L, then X₄is L. In some embodiments, when X₉X₁₀is N T, then X₁₁is Y.
Noting in particular that the VL CDR1 sequences of SEQ ID NOs: 86-88 are quite distinct from the others in FIG. 11, an alternative consensus sequence is VL CDR1 Motif 2:
(SEQ ID NO: 133)

X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁

where X₁is Q, N, K or R; X₂is S, T, C, N or Q; X₃is I, L, V, M or A; X₄is V, L, I, M or A; X₅is H, K or R; X₆is S, T or C; X₇is N or Q; X₈is G or A; X₉is N or Q; X₁₀is T, S or C; and X₁₁is Y, F or W. In some embodiments, X₁is limited to Q or K; and/or X₂is limited to S or N; and/or X₃is limited to I or L; and/or X₄is limited to V or L; and/or X₅is limited to H; and/or X₆is limited to S; and/or X₇is limited to N; and/or X₈is limited to G; and/or X₉is limited to N; and/or X₁₀is limited to T; and/or X₁₁is limited to Y. In some embodiments, the subsequence X₁X₂X₃is limited to Q N I; in some embodiments, the subsequence X₁X₂X₃is limited to Q S L; and in some embodiments, the subsequence X₁X₂X₃is limited to K S L. In addition, in some embodiments, when X₁X₂X₃is Q S L or Q N I, then X₄is V; whereas in other embodiments, when X₁X₂X₃is K S L, then X₄is L. In some embodiments, when X₉X₁₀is N T, then X₁₁is Y.
For the VL CDR2, one consensus sequence is VL CDR2 Motif 1:
(SEQ ID NO: 134)

Y₁ Y₂ Y₃

where Y₁is K, R or H; Y₂is V, I, L, M, A, T, S or C; and Y₃is S, T, C, N or Q. In some embodiments, Y₂is limited to V, I, M or T; and/or Y₃is limited to S or N.
Noting in particular that the VL CDR2 sequences of SEQ ID NO: 94 is quite distinct from the others in FIG. 11, an alternative consensus sequence is VL CDR2 Motif 2:
(SEQ ID NO: 135)

Y₁ Y₂ Y₃

where Y₁is D or E; Y₂is N or Q; and Y₃is N or Q. In some embodiments, Y₁is limited to D; and/or Y₂is limited to N; and/or Y₃is limited to N.
Similarly, noting that the VL CDR2 sequences of SEQ ID NO: 95 is quite distinct from the others in FIG. 11, an alternative consensus sequence is VL CDR2 Motif 3:
(SEQ ID NO: 136)

Y₁ Y₂ Y₃

where Y₁is Q or N; Y₂is D or E; and Y₃is K, R or H. In some embodiments, Y₁is limited to Q; and/or Y₂is limited to D; and/or Y₃is limited to K.
For the VL CDR3, one consensus sequence is VL CDR3 Motif 1:
(SEQ ID NO: 137)

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀

where Z₁is S, T, C, F, Y, M, L, V, I or A; Z₂is Q, N, S, T or C; Z₃is 5, T, C, G, A, H, K, R, Q, N, Y, F or W; Z₄is A, G, S, T, C, L, I, V, M, D or E; Z₅is H, K, R, E, D, S, T or C; Z₆is V, L, I, M, A, Y, F, W, S, T or C; Z₇is P, S, T, C or absent; Z₈is 5, T, C or absent; Z₉is W, P, L, I, V, M, A, F, or Y; and Z₁₀is T, S, C, V, L, I, M, A. In some embodiments, Z₁is limited to S, F, M or L; and/or Z₂is limited to Q or S; and/or Z₃is limited to S, G, H, Q or Y; and/or Z₄is limited to A, S, T, L, or D; and/or Z₅is limited to H, E, D or S; and/or Z₆is limited to V, Y, F, or S; and/or Z₇is limited to P, S or absent; and/or Z₈is limited to S or absent; and/or Z₉is limited to W, P, L or F; and/or Z₁₀is limited to T or V.
Noting in particular that the VL CDR3 sequences of SEQ ID NOs: 96-98 have a positive charge at position Z₅whereas the others in FIG. 11 do not, an alternative consensus sequence is VL CDR3 Motif 2:
(SEQ ID NO: 138)

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀

where Z₁is S, T, C, F or Y; Z₂is Q or N; Z₃is 5, T, C, G or A; Z₄is A, G, S, T or C; Z₅is H, K or R; Z₆is V, L, I, M or A; Z₇is P or absent; Z₈is absent; Z₉is W, P, L, I, V, M, A, F or Y; and Z₁₀is T, S, or C. In some embodiments, Z₁is limited to S or F; and/or Z₂is limited to Q; and/or Z₃is limited to S or G; and/or Z₄is limited to A, S or T; and/or Z₅is limited to H; and/or Z₆is limited to V; and/or Z₇is limited to P or absent; and/or Z₈is limited to absent; and/or Z₉is limited to W, P, L or F; and/or Z₁₀is limited to T.
Noting in particular that the VL CDR3 sequences of SEQ ID NOs: 99-102 have a negative charge at position Z₅whereas the others in FIG. 11 do not, an alternative consensus sequence is VL CDR3 Motif 3:
(SEQ ID NO: 139)

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀

where Z₁is M, C, L, I, V, A; Z₂is Q or N; Z₃is H, K, R, Q, N, G, A, Y or F; Z₄is L, I, V, M, A, D or E; Z₅is E or D; Z₆is Y or F; Z₇is P; Z₈is absent; Z₉is W, P, L, I, V, M, A, F or Y; and Z₁₀is T, S, or C. In some embodiments, Z₁is limited to M or L; and/or Z₂is limited to Q; and/or Z₃is limited to H, Q, G or Y; and/or Z₄is limited to L or D; and/or Z₅is limited to E or D; and/or Z₆is limited to Y or F; and/or Z₇is limited to P; and/or Z₈is limited to absent; and/or Z₉is limited to W, P, L or F; and/or Z₁₀is limited to T.
Noting in particular that the VL CDR3 sequence of SEQ ID NO: 103 is quite distinct from the others in FIG. 11, an alternative consensus sequence is VL CDR3 Motif 4:
(SEQ ID NO: 140)

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀

where Z₁is S, T or C; Z₂is 5, T or C; Z₃is Y or F; Z₄is T, S, or C; Z₅is 5, T or C; Z₆is 5, T or C; Z₇is 5, T or C; Z₈is 5, T or C; Z₉is W, P, F or Y; and Z₁₀is V, L, I, M, A, T, S or C. In some embodiments, Z₁is limited to S or T; and/or Z₂is limited to S or T; and/or Z₃is limited to Y; and/or Z₄is limited to T or S; and/or Z₅is limited to S or T; and/or Z₆is limited to S or T; and/or Z₇is limited to S or T; and/or Z₈is limited to S or T; and/or Z₉is limited to W, P or F; and/or Z₁₀is limited to V, L, I, T or S. In some embodiments, Z₁is limited to S; and/or Z₂is limited to S; and/or Z₃is limited to Y; and/or Z₄is limited to T; and/or Z₅is limited to S; and/or Z₆is limited to S; and/or Z₇is limited to S; and/or Z₈is limited to S; and/or Z₉is limited to W; and/or Z₁₀is limited to V.
Finally, noting in particular that the VL CDR3 sequence of SEQ ID NO: 104 is quite distinct from the others in FIG. 11, an alternative consensus sequence is VL CDR3 Motif 5:
(SEQ ID NO: 141)

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀

where Z₁is Q or N; Z₂is A or G; Z₃is W, Y or F; Z₄is D or E; Z₅is 5, T or C; Z₆is R, K or H; Z₇is T, S or C; Z₈is V, I, L, M or A; Z₉is V, I, L, M or A; and Z₁₀is I, L, V, M or A. In some embodiments, Z₁is limited to Q; and/or Z₂is limited to A; and/or Z₃is limited to W; and/or Z₄is limited to D; Z₅is limited to S; and/or Z₆is limited to R; and/or Z₇is limited to T; and/or Z₈is limited to V; and/or Z₉is limited to V; and/or Z₁₀is limited to I.
Variable Heavy Chain Sequences
VH of 1N23. Positive VH clones from the 1N23 hybridoma were sequenced and all four were found to encode functional VH chains. These four clones were designated 1N23VH3-5, 1N23VH3-7, 1N23VH2-1 and 1N23VH1-5.
VH of 1K23. Positive VH clones from the 1K23 hybridoma were sequenced and six were found to encode functional VH chains. These six clones were designated 1K23VH2-1_0910, 1K23VH1-4_0907, 1K23VH1-10_0907, 1K23VH8-4_0907, 1K23VH8-5_0907 and 1K23VH8-9_0907.
VH of 2K4. Positive VH clones from the 2K4 hybridoma were sequenced and four were found to encode functional VH chains. These four clones were designated 2K4VH3-8, 2K4VH2-8, 2K4VH1-1 and 2K4VH1-4.
VH of 1C9. Positive VH clones from the 1C9 hybridoma were sequenced and eight were found to encode functional VL chains. These eight clones included four unique sequences which are designated 1C9VH2-404-8_1024, 1C9VH2-405-12_1024, 1C9VH2-411-1_1024 and 1C9VH2-406-4_1024.
VH of 1J20. Positive VH clones from the 1J20 hybridoma were sequenced and two were found to encode functional VH chains. These two clones were designated 1J20VH1-7_0910 and 1J20VH1-1-6_0829.
VH of 1L20. Positive VH clones from the 1L20 hybridoma were sequenced and three were found to encode functional VH chains. These three clones were designated 1L20VH2-3_0903, 1L20VH2-1_0907 and 1L20VH2-3_0910.
VH of 1K3. Positive VH clones from the 1K3 hybridoma were sequenced and five were found to encode functional VH chains. These five clones were designated 1K3VH6-7, 1K3VH6-8_0816, 1K3VH3-4, 1K3VH3-4 and 1K3VH3-3_0816.
VH of 1L5. Positive VH clones from the 1L5 hybridoma were sequenced and nine were found to encode functional VH chains. These nine clones were designated 1L5VH003-5-8_0907, 1L5VH003-6-3_0907, 1L5VH001-7-6_0907, 1L5VH001-6-5_0907, 1L5VH001-6-11_0907, 1L5VH003-6-2_0910, 1L5VH001-6-12_0907, 1L5VH003-3-4_0907 and 1L5VH003-3-8_0907.
Additional VHs. VH sequences were obtained for four additional hybridoma antibodies designated CTA5_VH, CTB11_VH, CTC2_VH, CTD2_VH.
VH Sequence Alignments. Alignments of all of the VH sequences described above are shown in FIG. 10. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.
Unique VH CDR Sequences. Alignments of the unique CDR sequences of the VHs of FIG. 10 are shown in FIG. 12. Of the 43 VH sequences, there are only 8 unique CDR1 sequences, 9 unique CDR2 sequences and 10 unique CDR3 sequences, as shown in FIG. 12.
VH CDR Consensus Sequences. Based on the sequences disclosed in FIG. 12, as well as structure/function characteristics of the naturally occurring amino acids, consensus sequences for the VH CDRs can be determined.
For the VH CDR1, one consensus sequence is VH CDR1 Motif 1:
(SEQ ID NO: 142)

X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈

where X₁is G or A; X₂is Y, F, W, D or E; X₃is T, S, C or M; X₄is F, Y, W, V, L, I, M or A; X₅is T, S, C, N, or Q; X₆is S, T, C, A or G; X₇is Y, F, W, N, Q, G or A; and X₈is W, A, G, Y or F. In some embodiments, X₁is limited to G; and/or X₂is limited to Y, F or D; and/or X₃is limited to T or S; and/or X₄is limited to F or V; and/or X₅is limited to T, S or N; and/or X₆is limited to S, T or A; and/or X₇is limited to Y, F, N or G; and/or X₈is limited to W, A or Y. In some embodiments, the subsequence X₁X₂X₃is limited to G Y T; and in some embodiments, the subsequence X₁X₂X₃is limited to G F T. In addition, in some embodiments, the subsequence X₁X₇X₈is limited to S Y W.
Noting in particular that the VH CDR1 sequence of SEQ ID NOs: 109-110 and 112 are quite distinct from the others in FIG. 12, an alternative consensus sequence is VH CDR1 Motif 2:
(SEQ ID NO: 143)

X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈

where X₁is G or A; X₂is Y, F or W; X₃is T, S, C or M; X₄is F, Y or W; X₅is T, S or C; X₆is S, T or C; X₇is Y, F or W; and X₈is W. In some embodiments, X₁is limited to G; and/or X₂is limited to Y or F; and/or X₃is limited to T or S; and/or X₄is limited to F; and/or X₅is limited to T or S; and/or X₆is limited to S or T; and/or X₇is limited to Y or F; and/or X₈is limited to W. In some embodiments, the subsequence X₁X₂X₃is limited to G Y T; and in some embodiments, the subsequence X₁X₂X₃is limited to G F T. In addition, in some embodiments, the subsequence X₁X₇X₈is limited to S Y W.
For the VH CDR2, one consensus sequence is VH CDR2 Motif 1:
(SEQ ID NO: 144)

Y₁ Y₂ Y₃ Y₄ Y₅ Y₆ Y₇ Y₈ Y₉ Y₁₀

where Y₁is I, L, V, M or A; Y₂is Y, F, H, R, K, S or T; Y₃is P, S, T, Y, F, R, K or H; Y₄is G, A, S, T, K, R, H, D or E; Y₅is T, S or absent; Y₆is R, K, H or absent; Y₇is N, Q, D, E, G, A or absent; Y₈is G, A, S, T, Y or F; Y₉is D, E, A, G, N or Q; and Y₁₀is T, S, I, L, V, M, A, K, R or H. In some embodiments, Y₁is limited to I; and/or Y₂is limited to Y, H, R, K or S; and/or Y₃is limited to P, S, Y or R; and/or Y₄is limited to G, S, K or D; and/or Y₅is limited to T or absent; and/or Y₆is limited to R or absent; and/or Y₇is limited to N, D, G or absent; and/or Y₈is limited to G, A, S or Y; and/or Y₉is limited to D, E, A or N; and/or Y₁₀is limited to T, I or K.
Noting in particular that the VH CDR2 sequence of SEQ ID NO: 120-121 are quite distinct from the others in FIG. 12, an alternative consensus sequence is VH CDR2 Motif 2:
(SEQ ID NO: 145)

Y₁ Y₂ Y₃ Y₄ Y₅ Y₆ Y₇ Y₈ Y₉ Y₁₀

where Y₁is I, L, V, M or A; Y₂is Y, F, H, R, K, S or T; Y₃is P, S, T, Y or F; Y₄is G, A, S, T, K, R or H; Y₅is T, S or absent; Y₆is R, K, H or absent; Y₇is N, Q, D, E or absent; Y₈is G, A, S, T, Y or F; Y₉is D, E, A, G, N or Q; and Y₁₀is T, S, I, L, V, M or A. In some embodiments, Y₁is limited to I; and/or Y₂is limited to Y, H, R or S; and/or Y₃is limited to P, S or Y; and/or Y₄is limited to G, S or K; and/or Y₅is limited to T or absent; and/or Y₆is limited to R or absent; and/or Y₇is limited to N, D or absent; and/or Y₈is limited to G, A, S or Y; and/or Y₉is limited to D, E, A or N; and/or Y₁₀is limited to T or I.
For the VH CDR3, one consensus sequence is VH CDR3 Motif 1:
(SEQ ID NO: 146)

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀ Z₁₁ Z₁₂ Z₁₃ Z₁₄ Z₁₅

where Z₁is A, G, V, L, I or M; Z₂is R, K, H, C or M; Z₃is G, A, R, K, H, S, T, Y, F, W, D, E or absent; Z₄is Y, F, W, N, Q, G, A, R, K, H or absent; Z₅is S, T, N, Q, E, D or absent; Z₆is D, E or absent; Z₇is L, I, V, M, A, S, T or absent; Z₈is L, I, V, M, A or absent; Z₉is G, A, R, K, H or absent; Z₁₀is I, L, V, M, A, N, Q, R, K, H or absent; Z₁₁is A, M, F, Y, W, S, T, G or absent; Z₁₂is W, Y, F, A, G or absent; Z₁₃is F, Y, W, G, A, M or C; Z₁₄is A, G, M, D, E, W, Y or F; and Z₁₅is Y, F, W, G, A or V. In some embodiments, Z₁is limited to A or V; and/or Z₂is limited to R, K or C; and/or Z₃is limited to G, R, S, Y, D or absent; and/or Z₄is limited to Y, N, G, R or absent; and/or Z₅is limited to S, N, E or absent; and/or Z₆is limited to D or absent; and/or Z₇is limited to L, S or absent; and/or Z₈is limited to L or absent; and/or Z₉is limited to G, R or absent; and/or Z₁₀is limited to I, N, R, L or absent; and/or Z₁₁is limited to A, F, S, G or absent; and/or Z₁₂is limited to W, Y, A or absent; and/or Z₁₃is limited to F, Y, G or M; and/or Z₁₄is limited to A, D, W or Y; and/or Z₁₅is limited to Y, F, W or G.
Although the disclosed subject matter has been described and illustrated in the foregoing exemplary embodiments, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the details of implementation of the disclosed subject matter may be made without departing from the spirit and scope of the disclosed subject matter, which is limited only by the claims which follow.

Claims

We claim:

1. A cell transformed with a nucleic acid molecule encoding a heavy chain or light chain of an antibody that specifically binds to a human VASA protein comprising an immunoglobulin heavy chain and an immunoglobulin light chain,

a) wherein the variable region of said light chain comprises:

(i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 83-88;

(ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 89-95; and

(iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-104; and

b) wherein the variable region of said heavy chain comprises:

(i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112;

(ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 113-121; and

(iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 122-131.

2. The cell of claim 1, wherein said nucleic acid molecule is selected from the group consisting of a cloning vector, an expression vector, a heterologous recombination vector, and a viral integration vector.

3. The cell of claim 1, wherein said cell is a mammalian cell.

4. The cell of claim 3, wherein said cell is a rodent cell.

5. The cell of claim 3, wherein said cell is a Chinese Hamster Ovary (CHO) cell.

6. The cell of claim 3, wherein said cell is a human cell.